A Phase 1, Multi-center, Open-Label Dose Escalation Study of SYN004 in Patients With Solid Tumors to Evaluate the Safety, Immunogenicity and Pharmacokinetics of SYN004 Following Administration of Eight Intravenous Doses
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2016
At a glance
- Drugs SYN 004 Synermore Biologics (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Synermore Biologics
- 17 Oct 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2017.
- 17 Oct 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.
- 17 Oct 2016 Status changed from not yet recruiting to recruiting.